Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ensysce Biosciences, Inc. on October 27, 2022. The report details a corporate action regarding the Company's capital structure, specifically a reverse stock split of its Common Stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the amendment to the Certificate of Incorporation.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-20 reverse stock split effective at 12:01 am on October 28, 2022.
- Share Consolidation: Every 20 pre-split shares were combined into 1 post-split share.
- Trading Details: Post-split Common Stock began trading on October 28, 2022, under a new CUSIP number (293602207).
- Ownership Impact: The split does not alter any stockholder's ownership percentage, authorized share count, par value, or voting rights.
- Adjustments: Exercise prices and share counts for outstanding warrants, stock options, and restricted stock units were automatically adjusted proportionately. Fractional shares were rounded up to the nearest whole share.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the mechanics of the stock split. The action was authorized by stockholders at a special meeting on September 8, 2022, and executed by the Board of Directors.
Investor Verification Checklist
- Verify the new CUSIP number (293602207) for post-split trading.
- Confirm the adjusted exercise prices and share quantities for any held warrants, options, or RSUs.
- Check brokerage statements to ensure fractional shares were rounded up correctly.
- Review the Certificate of Amendment (Exhibit 3.1) for legal specifics of the capital structure change.